Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0D9817N)
Alzheimer's Association (ZEN-17-441253)
H2020 European Research Council (ERC-CELLPHASE-AD -834682)
Ministerio de Ciencia, Innovación y Universidades (RTI2018-101850-A-100)
Ikerbasque, Basque Foundation for Science (startup funds)
Received: 19 November 2020
Accepted: 21 August 2021
First Online: 25 September 2021
: All animal experiments were conducted according to protocols approved by the local Ethical Committee of Laboratory Animals of the KU Leuven (governmental licence LA1210591) following governmental and EU guidelines. All experiments conformed to the relevant regulatory standards. The consent for reprogramming human somatic cells to hiPSCs was carried out on ESCRO protocol 19 − 04 at Mount Sinai (J.TCW.). The autopsies were performed with informed consent in accordance with the applicable laws in Belgium (UZ Leuven) and Germany (Ulm, Bonn and Offenbach). The use of human brain tissue samples for this study was approved by the ethical committees of Leuven University and UZ Leuven.
: Not applicable.
: BDS is a consultant for Eisai. DRT received speaker honorarium from Novartis Pharma Basel (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK), and UCB (Belgium), and collaborated with GE-Healthcare (UK), Novartis Pharma Basel (Switzerland), Probiodrug (Germany), and Janssen Pharmaceutical Companies (Belgium). PP, JTCW, AS, SC, MAT, NC, SM, AMG and AMA declare that they have no competing interests.